Business Context and Reporting Period
This Form 8-K Current Report was filed by Abbott Laboratories on November 30, 2015. The filing addresses a temporary suspension of trading under the company's employee benefit plans, specifically the Abbott Laboratories Stock Retirement Plan (U.S. Plan) and the Abbott Laboratories Stock Retirement Plan (Puerto Rico).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is administrative in nature and does not contain financial performance data.
Material Changes
The material change reported is the implementation of a "Blackout Period" for the company's employee benefit plans. This suspension is necessitated by administrative changes, including:
- Changing the recordkeeper.
- Changing the trustee of the U.S. Plan.
- Changing the custodian of the P.R. Plan.
Outlook, Risks, and Unusual Items
Blackout Period Details:
- Expected Start: January 7, 2016, at 2 p.m. CST.
- Expected End: During the week of January 24, 2016.
- Restrictions: During this period, participants cannot change contribution rates, direct or diversify investments (including Abbott common shares), or obtain loans, withdrawals, or distributions.
Executive Trading Restrictions: On December 2, 2015, the company notified directors and executive officers of the Blackout Period. Pursuant to Section 306 of the Sarbanes-Oxley Act and Rule 104 of Regulation BTR, restrictions on trading Abbott common stock (including derivatives) apply to these individuals during the Blackout Period.
Investor Verification Checklist
- Verify the actual start and end dates of the Blackout Period, as the filing only provides expected dates.
- Confirm the specific administrative changes (recordkeeper, trustee, custodian) once finalized.
- Review the attached Exhibit 99.1 for the full text of the notice provided to directors and executive officers regarding trading restrictions.